Literature DB >> 11343339

Aberrant splicing at catalytic site as cause of infantile onset glycogen storage disease type II (GSDII): molecular identification of a novel IVS9 (+2GT-->GC) in combination with rare IVS10 (+1GT-->CT).

M Stroppiano1, G Bonuccelli, F Corsolini, M Filocamo.   

Abstract

Glycogen storage disease type II (GSDII) results from deleterious mutations in acid alpha-glucosidase gene. To date several mutant alleles have been studied including missense and nonsense mutations, insertions, small and large deletions as well as splice site mutations. Apart from IVS1 (- 13-->G), 525delT, and Delta18, the other mutations are rare and often unique to single patients. Moreover, the molecular findings also observed in the different ethnic groups makes it difficult to attempt to correlate genotype and phenotype to explain the origin of clinical variability. Even though there are no conclusive genotype phenotype correlations, the in frame splice site mutations identified up until now have been found associated with the juvenile/adult onset of GSDII. In this study we describe a novel in frame splicing defect, IVS9 (+2GT-->GC), identified in combination with the rare IVS10 (+1GT-->CT) mutation in a patient with classic infantile GSDII disease. Because both mutations occur at the catalytic site region, it is likely that the alteration of both catalytic function and steric conformation of the enzyme may be responsible for the most severe form of the disease. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343339     DOI: 10.1002/ajmg.1310

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  5 in total

1.  Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.

Authors:  Stefania Zampieri; Emanuele Buratti; Silvia Dominissini; Anna Lisa Montalvo; Maria Gabriela Pittis; Bruno Bembi; Andrea Dardis
Journal:  Eur J Hum Genet       Date:  2010-12-22       Impact factor: 4.246

2.  c.1437G>A intron 9 substitution on acid α-glucosidase gene associated with classic infantile-onset Pompe disease phenotype.

Authors:  Andrés Morales; Mikaela I Poling; Marco T Páez; Julio Cabrera; Rodger J McCormick
Journal:  BMJ Case Rep       Date:  2015-07-09

3.  Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.

Authors:  Deeksha S Bali; Jennifer L Goldstein; Suhrad Banugaria; Jian Dai; Joanne Mackey; Catherine Rehder; Priya S Kishnani
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

4.  Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.

Authors:  Jousef Alandy-Dy; Marie Wencel; Kathy Hall; Julie Simon; Yanjun Chen; Erik Valenti; Jade Yang; Deeksha Bali; Anita Lakatos; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Ann Transl Med       Date:  2019-07

5.  Familial adult-onset Pompe disease associated with unusual clinical and histological features.

Authors:  Lorenzo Maggi; Franco Salerno; Cinzia Bragato; Simona Saredi; Flavia Blasevich; Elio Maccagnano; Barbara Pasanisi; Cesare Danesino; Marina Mora; Lucia Morandi
Journal:  Acta Myol       Date:  2013-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.